Description
Humana Flow Cytometry in Hematopathology A Visual Approach to Data Analysis and Interpretation by Doyen T. Nguyen, Lawrence W. Diamond, Raul C. Braylan
The second edition of this volume reflects the recent advances in the FCM analysis of hematopoietic disorders. The chapters have been revised to incorporate new text and figures. The volume is aimed at hematopathologists, hematologists, pathologists, and laboratory technicians._x000D_ Table of contents : - _x000D_
Table of Contents_x000D_
_x000D_
Preface to second edition_x000D_
Preface to first edition_x000D_
Acknowledgements_x000D_
List of Abbreviations_x000D_
List of Case Studies_x000D_
Color Plates_x000D_
_x000D_
Chapter 1 Approach to Flow Cytometry - General Considerations_x000D_
_x000D_
1.1 Reasons for the necessity of proper data analysis_x000D_
1.1.1 The pitfalls of the FCM data format of 'percent positive' per_x000D_
antibody tested_x000D_
1.2 General aspects of FCM data analysis and interpretation_x000D_
1.3 Other applications of FCM in hematopathology_x000D_
1.4 Maturation and differentiation of hematopoietic elements, an_x000D_
overview based on the immunologic markers currently in use in the FCM_x000D_
laboratory_x000D_
_x000D_
Chapter 2 FCM immunophenotyping and DNA analysis - Practical aspects_x000D_
that can affect data analysis and interpretation _x000D_
_x000D_
2.1 Sample selection_x000D_
2.1.1 Liquid specimens_x000D_
2.1.2 Solid tissue specimens_x000D_
2.2 Preparing nucleated cell suspensions_x000D_
2.3 Cell yield and viability_x000D_
2.4 Sample staining._x000D_
2.4.1 Surface antigens_x000D_
2.4.2 Intracellular antigens_x000D_
2.4.3 DNA content_x000D_
2.5 Data acquisition_x000D_
2.5.1 Calibration_x000D_
2.5.2 Color compensation_x000D_
2.5.3 List mode data collection _x000D_
2.5.4 Exclusion of nonviable cells_x000D_
2.6 Antibody panel design_x000D_
2.6.1 Antibody selection_x000D_
2.6.1.1 Anti-light chain antibodies_x000D_
2.6.2 Fluorochrome conjugation_x000D_
2.7 Comprehensive antibody panels_x000D_
2.7.1 Disease-oriented antibody panels_x000D_
2.7.2 Antibody panels oriented by specimen type_x000D_
2.8 Tailored panels and add-on testing_x000D_
2.8.1 Minimal residual disease_x000D_
2.9 FCM immunophenotyping data representation_x000D_
2.9.1 Analysis panels_x000D_
2.9.2 Color display_x000D_
2.10 Approach to DNA data analysis_x000D_
2.10.1 DNA ploidy_x000D_
2.10.2 S-phase_x000D_
_x000D_
Chapter 3 FCM data analysis on nearly homogeneous samples_x000D_
_x000D_
3.1 FCM parameters_x000D_
3.1.1 Forward scatter_x000D_
3.1.2 Side scatter_x000D_
3.1.3 Fluorescence_x000D_
3.1.3.1 Heterogeneous fluorescence intensity (bimodal, variable)_x000D_
3.2 Fluorescence dynamic range_x000D_
3.3 Strategy to the visual review of FCM immunophenotyping data_x000D_
3.4 Common SSC/CD45 patterns_x000D_
3.4.1 Assessment of the blast population_x000D_
3.4.2 Immature neoplastic cells with downregulated CD45_x000D_
3.4.3 SSC/CD45 in mature lymphoid disorders_x000D_
3.5 Other dot plot patterns useful in acute leukemia diagnosis_x000D_
3.5.1 Useful antigenic features in AML_x000D_
3.5.1.1 Myeloid phenotypic abnormalities and MRD detection _x000D_
3.5.2 Precursor B-ALL vs bone marrow B-cell progenitors_x000D_
3.5.3 Useful antigenic features in precursor T-lymphoma/leukemia_x000D_
3.6 Evaluation of mature lymphoid malignancies_x000D_
3.6.1 Assessment of surface light chain expression_x000D_
3.6.2 Assessment of pan B-cell antigens_x000D_
3.6.3 Useful antigenic features in mature B-cell malignancies_x000D_
3.6.3.1 CD10 expression: Follicular center cell lymphomas_x000D_
3.6.3.2 Pattern of CD20 and CD11c coexpression_x000D_
3.6.3.3 CD5 expression_x000D_
3.6.3.4 Aberrant B-cell profile_x000D_
3.6.4 Identification of abnormal mature T-cells_x000D_
3.6.5 Useful antigenic features in mature T-cell malignancies_x000D_
3.7 Assessing the biological behavior of mature lymphoid neoplasms_x000D_
3.8 Dot plot patterns in histiocytic proliferations and_x000D_
nonhematopoietic malignancies_x000D_
_x000D_
Chapter 4 FCM data analysis on heterogeneous specimens_x000D_
_x000D_
4.1 Identifying normal FCM samples_x000D_
4.1.1 Benign/reactive solid lymphoid tissue (e.g., lymph nodes,_x000D_
tonsils)_x000D_
4.1.1.1 Pattern of CD10/CD20 coexpression. Distinction between FRFH_x000D_
and FCC lymphoma_x000D_
4.1.2 Normal peripheral blood and normal bone marrow_x000D_
4.1.2.1 Blast region_x000D_
4.1.2.2 Bone marrow B-cell precursors_x000D_
4.1.2.3 Lymphocytes_x000D_
4.1.2.4 Monocytes_x000D_
4.1.2.5 Plasma cells_x000D_
4.1.2.6 Erythroid precursors_x000D_
4.1.2.7 Maturing myeloid cells_x000D_
4.2 Abnormal heterogeneous samples with a detectable immature_x000D_
neoplastic population_x000D_
4.2.1 Blasts of lymphoid lineage_x000D_
4.2.2 Blasts of myeloid lineage_x000D_
4.2.2.1 AML_x000D_
4.2.2.2 High-grade MDS and MPD with increased blasts_x000D_
4.3 Minimal residual disease_x000D_
4.4 Abnormal heterogeneou_x000D_